Compare EBON & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBON | ATHA |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4M | 18.2M |
| IPO Year | 2020 | 2020 |
| Metric | EBON | ATHA |
|---|---|---|
| Price | $3.50 | $7.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.1K | ★ 3.1M |
| Earning Date | 08-15-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,337,066.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 104.28 | N/A |
| 52 Week Low | $3.00 | $2.20 |
| 52 Week High | $7.15 | $8.36 |
| Indicator | EBON | ATHA |
|---|---|---|
| Relative Strength Index (RSI) | 38.20 | 83.94 |
| Support Level | $3.31 | $3.80 |
| Resistance Level | $3.63 | $8.36 |
| Average True Range (ATR) | 0.18 | 0.39 |
| MACD | 0.02 | 0.27 |
| Stochastic Oscillator | 11.12 | 66.23 |
Ebang International Holdings Inc is a blockchain technology and Fintech company, that has ASIC chip design capability. Its business is ASIC chip design and Telecommunication. It operates in a single segment selling bitcoin mining machines and related accessories, telecommunication products, providing cryptocurrency exchange services, management and maintenance services, and cross-border payment and foreign exchange services and rental services. Its geographic regions are Mainland China, and Australia.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.